Related Experiment Video
Updated: May 23, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Psoriasis and cardiovascular disorders
1Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA. caitriona.ryan@baylorhealth.edu
Insights
Patients with moderate-to-severe psoriasis face higher cardiovascular disease risks due to shared inflammatory pathways. Psoriasis treatments may impact cardiovascular health, requiring careful consideration of therapy choices.
Area of Science:
- Dermatology and Cardiology
- Inflammation and Immunology
Background:
- Moderate-to-severe psoriasis is linked to increased cardiovascular disease (CVD) risk and associated factors like obesity and diabetes.
- Shared inflammatory pathways are implicated in the pathophysiology of psoriasis, obesity, and coronary artery disease.
Purpose of the Study:
- To review the association between psoriasis and cardiovascular disorders.
- To evaluate the impact of current psoriasis therapies on cardiovascular risk.
Main Methods:
- Review of existing evidence on psoriasis and cardiovascular comorbidities.
- Analysis of studies on the cardiovascular effects of psoriasis treatments, including methotrexate, anti-TNF-a agents, and anti-interleukin-12p40 antibodies.
Main Results:
- Retrospective studies suggest potential cardio-protective effects of methotrexate and anti-TNF-a agents.
- Concerns exist regarding potential excess cardiovascular events with newer anti-interleukin-12p40 antibody therapies.
Conclusions:
- Understanding the link between psoriasis and CVD is crucial for patient management.
- The choice of psoriasis therapy may influence cardiovascular risk, necessitating further investigation.
Abstract:
There is considerable evidence to show that patients with moderate-to-severe psoriasis have a significantly increased risk of cardiovascular disease and cardiovascular risk factors such as obesity, diabetes mellitus, the metabolic syndrome and smoking compared to the general population. The mechanistic link between psoriasis and this observed increase in cardiovascular co-morbidities has not been fully defined. It is clear, however, that common inflammatory pathways are at play in the pathophysiology of psoriasis, obesity and coronary artery disease. It had been proposed that the control of systemic inflammation in psoriasis could help reduce cardiovascular morbidity, and retrospective studies of methotrexate and anti-TNF-a agents have suggested a cardio-protective effect with use of these agents. More recently, however, there have been concerns regarding a potential excess of cardiovascular events with the newer generation of anti-interleukin-12p40 antibodies. In this article we review the association of psoriasis with cardiovascular disorders and the effects of current psoriasis therapies on cardiovascular risk.
Related Concept Videos
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease I: Introduction
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.